ENTITY
CStone Pharmaceuticals

CStone Pharmaceuticals (2616 HK)

89
Analysis
Health CareHong Kong
CStone Pharmaceuticals operates as a biotechnology company. The Company develops immuno-oncology and molecularly targeted drugs to address unmet medical needs for cancer patients. CStone Pharmaceuticals serves customers worldwide.
more
Refresh
bullishWuxi Biologics
23 Mar 2019 12:52

ECM Weekly (23 March 2019) - ESR, Sun Car, Ruhnn, CanSino, Frontage, Wuxi Bio, WiseTech,

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
18 Mar 2019 17:41

CanSino Biologics (康希诺) IPO: Valuation Attractive, Lilly Asia Doubling Up (Part 4)

CanSino Biologics started its book building today to raise up to USD 160 million to list in Hong Kong. In our previous insights (links provided...

Logo
813 Views
Share
26 Feb 2019 15:21

CStone Pharma (基石药业) Post-IPO: Strong Debut but Lacks near Term Catalysts

CStone Pharma's IPO was priced at HKD 12.00/share and started trading today. In this insight, we summarize the allocation, the use of proceeds and...

Logo
549 Views
Share
23 Feb 2019 12:12

ECM Weekly (23 February 2019) - Futu, CStone, Dexin, New Century, AB InBev, MabPharma

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
11 Feb 2019 14:15

CStone Pharma (基石药业) IPO: Thoughts on Valuation (Part 2)

CStone Pharma, a Wuxi Apptec related biotech company, plans to raise USD 300m to list on the Hong Kong Stock Exchange. In our previous insight...

Logo
758 Views
Share
x